The Nerve of Glaucoma

Archives of Ophthalmology

Volumn 112, Issue 1, 1994, Pages 37-44

  Schumer, Robert A ^a   Podos, Steven M ^a,b,c,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

^c ALCON RESEARCH LTD   (United States)

^d Pharmos Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; GROWTH FACTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXYGEN RADICAL; PHENYTOIN; SCAVENGER;

GLAUCOMA; GROWTH STIMULATION; HYPOXIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; NERVE DEGENERATION; NERVE REGENERATION; NEUROTROPISM; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTIOXIDANTS; CALCIUM CHANNEL BLOCKERS; FREE RADICAL SCAVENGERS; GLAUCOMA, OPEN-ANGLE; GROWTH SUBSTANCES; HUMAN; NERVE REGENERATION; NITRIC OXIDE; OPTIC NERVE; OPTIC NERVE DISEASES; RECEPTORS, N-METHYL-D-ASPARTATE; SUPPORT, NON-U.S. GOV'T;

EID: 0028158162     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archopht.1994.01090130047015     Document Type: Article

References (156)

1. Armaly MF, Krueger DE, Maunder L, et al. Biostatistical analysis of the Collaborative Glaucoma Study, I: summary report of the risk factors for glaucomatous visual-field defects. Arch Ophthalmol. 1980;98:2163–2171.
2. Perkins ES. The Bedford Glaucoma Survey, I: long-term follow-up of borderline cases. Br J Ophthalmol. 1975;57:179–185.
3. Kitazawa Y, Horie T, Aoki S, et al. Untreated ocular hypertension. Arch Ophthalmol. 1977;95:1180–1184.
4. Hollows FC, Graham PA. Intraocular pressure, glaucoma and glaucoma suspects in a defined population. Br J Ophthalmol. 1966;50:570–586.
5. Kahn HA, Milton RC. Alternative definitions of open-angle glaucoma: effect on prevalence and association in the Framingham Eye Study. Arch Ophthalmol. 1980;98:2172–2177.
6. Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol. 1989;107:186–188.
7. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. Arch Ophthalmol. 1991;109:1090–1095.
8. Bankes JLK, Perkins ES, Tsolakis S, et al. Bedford Glaucoma Survey. BMJ. 1968;1:791–796.
9. Schulzer M, Drance SM, Carter CJ, Brooks DE, Douglas GR, Lau W. Biostatistical evidence for two distinct chronic open angle glaucoma populations. Br J Ophthalmol. 1990;74:196–200.
10. Chauhan BC, Drance SM. The relationship between intraocular pressure and visual field progression in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1992;30:521–526.
11. Wilson MR. Epidemiological features of glaucoma. Int Ophthalmol Clin. 1990;30:153–160.
12. Anderson DR. Glaucoma: the damage caused by pressure. XLVI Edward Jackson memorial lecture. Am J Ophthalmol. 1989;108:485–495.
13. Drance SM. Bowman Lecture. Glaucoma: changing concepts. Eye. 1992;6:337–345.
14. Van Buskirk ME, Cioffi GA. Glaucomatous optic neuropathy. Am J Ophthalmol. 1992;113:447–452.
15. Bassett AL, Bigger JT Jr, Hoffman BF. ‘Protective’ action of diphenylhydantoin on canine Purkinje fibers during hypoxia. J Pharmacol Exp Ther. 1970;173:336–343.
16. Becker B, Stamper RL, Asseff C, Podos SM. Effect of diphenylhydantoin on glaucomatous field loss: a preliminary report. Trans Am Acad Ophthalmol Otolaryngol. 1972;76:412–422.
17. Kitazawa Y, Shirai H, Go FJ. The effect of Ca2+-antagonist on visual field in low-tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 1989;227:408–412.
18. Gasser P, Flammer J, Guthauser U, Mahler F. Do vasospasms provoke ocular disease? Angiology. 1990;41:213–220.
19. Serle JB, Schmidt KG, Mittag TW, Schumer RA, Podos SM, Camras CB. Nifedipine and ocular blood flow. Invest Ophthalmol Vis Sci. 1992;33(Supplement):1279.
20. Netland PA, Chaturvedi N, Dreyer EB. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am J Ophthalmol. 1993;15:608–613.
21. Piltz JR, Bose S, Grunwald JE, Petrig BL, Riva CE. Effect of nimodipine on automated threshold perimetry, spatial contrast sensitivity and macular blood flow in normal tension glaucoma and controls. Invest Ophthalmol Vis Sci. 1993;34(Supplement):1287.
22. Levy JC. La recherche dans le glaucome vers une neuroprotection. In: Alain Bechetoille, ed. Normal Pressure Glaucomas. Angers, France: Japperenard; 1990:213–221.
23. Neufeld AH. Protection of the optic nerve in glaucoma. In: Drance SM, Van Buskirk EM, Neufeld AH, eds. Pharmacology of Glaucoma. Baltimore, Md: Williams & Wilkins; 1992;292–300.
24. Bresnick GH. Excitotoxins: A possible new mechanism for the pathogenesis of ischemic retinal damage. Arch Ophthalmol. 1989;107:339–341.
25. Shatz CJ, O'Leary DDM. Repair and replacement to restore sight. Arch Ophthalmol. 1993;111:472–477.
26. Choi DW, Hartley DM. Calcium and glutamate-induced cortical neuronal death. In: Waxman SG, ed. Molecular and Cellular Approaches to the Treatment of Neurological Disease. New York, NY: Raven Press; 1993.
27. Watkins JC, Evans RH. Excitatory amino acid transmitters. Ann Rev Pharmacol Toxicol. 1981;21:165–204.
28. Watkins JC, Krogsgaard-Larsen P, Honore T. Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol Sci. 1990;11:25–33.
29. Sommer B, Seeburg PH. Glutamate receptor channels: novel properties and new clones. Trends Pharmacol Sci. 1992;13:291–296.
30. Stevens CF. NMDA receptors: on to molecular mechanisms. Nature. 1992;358:18–19.
31. Daw NW, Stein PSG, Fox K. The role of NMDA receptors in information processing. Annu Rev Neurosci. 1993;16:207–222.
32. Albers GW, Goldberg MP, Choi DW. Do NMDA antagonists prevent neuronal injury? Yes. Arch Neurol. 1992;49:418–420.
33. Westbrook GL. Glutamate receptors and excitotoxicity. In: Waxman SG, ed. Molecular and Cellular Approaches to the Treatment of Neurological Disease. New York, NY: Raven Press; 1993.
34. Shimada N, Graf R, Rosner G, Heiss WD. Differences in ischaemia-induced accumulation of amino acids in the cat cortex. Stroke. 1990;21:1445–1451.
35. Beckman JS. The double-edged role of nitric oxide in brain function and superoxidemediated injury. J Dev Physiol. 1991;15:53–59.
36. Hansen AJ. Effect of anoxia on ion distribution in the brain. Physiol Rev. 1985;65:101–148.
37. Drejer J, Benveniste H, Diemer NH, Schousboe A. Cellular origin of ischemia-induced glutamate release from brain tissue in vivo and in vitro. J Neurochem. 1985;45:145–151.
38. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem. 1984;43:1369–1374.
39. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:623–634.
40. Olney JW. Glutamate-induced retinal degeneration in neonatal mice. J Neuropathol Exp Neurol. 1969;28:455–474.
41. Zhang D, Sucher NJ, Lipton SA. Heterogeneity of AMPA and kainate receptors in rat retinal ganglion cells: subunits, flips, and flops. Invest Ophthalmol Vis Sci. 1993;34(Supplement):1333.
42. Tung NN, Morgan IG, Ehrlich D. A quantitative analysis of the effects of excitatory neurotoxins on retinal ganglion cells in the chick. Vis Neurosci. 1990;4:217–223.
43. Sesma MA, Price MT, Olney JW. Sensitivity of retinal ganglion cell subtypes to specific excitotoxins. Invest Ophthalmol Vis Sci. 1991;32 (Supplement):1263.
44. Caprioli J, Kitano S. Large retinal ganglion cells are more susceptible to excitotoxic and hypoxic injury than small cells. Invest Ophthalmol Vis Sci. 1993;34(Supplement):1429.
45. Quigley HA, Sanchez RM, Dunkelberger GR, L'Hernault NL, Baginski TA. Chronic glaucoma selectively damages large optic nerve fibers. Invest Ophthalmol Vis Sci. 1987;28:913–920.
46. Dandona L, Hendrickson A, Quigley HA. Selective effects of experimental glaucoma on axonal transport by retinal ganglion cells to the dorsal lateral geniculate nucleus. Invest Ophthalmol Vis Sci. 1991;32:1593–1599.
47. Glovinsky Y, Quigley HA, Pease ME. Foveal ganglion cell loss is size dependent in experimental glaucoma. Invest Ophthalmol Vis Sci. 1993;34:395–400.
48. Dreyer EB, Lipton SA. A proposed role for excitatory amino acids in glaucoma visual loss. Invest Ophthalmol Vis Sci. 1993;34(Supplement): 1504.
49. Lustig HS, von Brauchitsch KL, Chan J, Greenberg DA. Ethanol and excitotoxicity in cultured cortical neurons: differential sensitivity of N-methyl-D-aspartate and sodium nitroprusside toxicity. J Neurochem. 1992;59:2193–2200.
50. Judge ME, Sheardown MJ, Jacobsen P, Honore T. Protection against post-ischemic behavioral pathology by the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f) quinoxaline (NBQX) in the gerbil. Neurosci Lett. 1991;133:291–294.
51. Pai KS, Ravindranath V. Toxicity of N-acetylaspartylglutamate and its protection by NMDA and non-NMDA receptor antagonists. Neurosci Lett. 1991;126:49–51.
52. Diemer NH, Jorgensen MB, Johansen FF, Sheardown M, Honore T. Protection against ischemic hippocampal CA1 damage in the rat with a new non-NMDA antagonist, NBQX. Acta Neurol Scand. 1992;86:45–49.
53. Bullock R, Graham DI, Chen MH, Lowe D, McCulloch J. Focal cerebral ischaemia in the cat: pretreatment with a competitive NMDA receptor antagonist, D-CPP-ene. J Cereb Blood Flow Metab. 1990;10:668–674.
54. Uematsu D, Araki N, Greenberg JH, Sladky J, Reivich M. Combined therapy with MK-801 and nimodipine for protection of ischemic brain damage. Neurology. 1991;41:88–94.
55. David P, Lusky M, Teichberg VI. Involvement of excitatory neurotransmitters in the damage produced in chick embryo retinas by anoxia and extracellular high potassium. Exp Eye Res. 1988;46:657–662.
56. Lucus DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch Ophthalmol. 1957;58:193–201.
57. Sucher NJ, Aizenman E, Lipton SA. N-methyl-D-aspartate antagonists prevent kainate neurotoxicity in rat retinal ganglion cells in vitro. J Neurosci. 1991;11:966–971.
58. Siliprandi R, Canella R, Carmignoto G, et al. N-methyl-D-aspartate—induced neurotoxicity in the adult rat retina. Vis Neurosci. 1992;8:567–573.
59. Steinberg GK, Kunis D, Saleh J, DeLaPaz R. Protection after transient focal cerebral ischemia by the N-methyl-D-aspartate antagonist dextrorphan is dependent upon plasma and brain levels. J Cereb Blood Flow Metab. 1991;11:1015–1024.
60. Yoon YH, Marmor MF. Dextromethorphan protects retina against ischemic injury in vivo. Arch Ophthalmol. 1989;107:409–411.
61. Lam TT, Stojack K, Siew E, Chu R, Tso MOM. Ameliorative effect of a N-methyl-D-aspartate receptor antagonist MK801 on retinal ischemia. Invest Ophthalmol Vis Sci. 1993;34(Supplement): 1431.
62. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci. 1991;11:1649–1659.
63. Appel SH. Excitotoxic neuronal cell death in amyotrophic lateral sclerosis. Trends Neural Sci. 1993;16:3–5.
64. Young AB. Role of excitotoxins in hereditodegenerative neurologic diseases. In: Waxman SG, ed. Molecular and Cellular Approaches to the Treatment of Neurological Disease. New York, NY: Raven Press; 1993.
65. Greenamyre JT, O'Brien CF. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol. 1991;48:977–981.
66. Porsche-Wiebking E. New N-methyl-D-aspartate antagonists for the treatment of stroke. Drug Devel Res. 1989;17:367–375.
67. Harrison MJG. Protection against ischaemia: the basis of acute stroke therapy. Curr Opin Neurol Neurosurg. 1992;5:33–38.
68. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254:1515–1518.
69. Hollmann M, O'Shea-Greenfield A, Rogers SW, Heinemann S. Cloning by functional expression of a member of the glutamate receptor family. Nature. 1989;342:643–648.
70. Ishii T, Moriyoshi K, Sugihara H, et al. Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. J Biol Chem. 1993;68:2836–2843.
71. Toni D, Frontoni M, Argentino C, Sacchetti ML, De Michele M, Fieschi C. Update on calcium antagonists in cerebrovascular diseases. J Cardiovasc Pharmacol. 1991;18(Supplement 8):S10-S14.
72. Nuglisch J, Karkhoutly C, Mennel HD, Rossberg C, Krieglstein J. Protective effect of nimodipine against ischaemic neuronal damage in rat hippocampus without changing postischaemic cerebral blood flow. J Cereb Blood Flow Metab. 1990;10:654–659.
73. Bean BP. Classes of calcium channels in vertebrate cells. Ann Rev Physiol. 1989;51:367–384.
74. Pauwels PJ, Leysen JE, Janssen PAJ. Ca++ and Na+ channels involved in neuronal cell death: protection by flunarizine. Life Sci. 1991;48:1881–1893.
75. Catterall WA, Striessnig J. Receptor sites for Ca2+ channel antagonists. Trends Pharmacol Sci. 1992;13:256–262.
76. Peters T, Wilffert PB, Vanhoutte PM, Van Zwieten PA. Calcium channels in the brain as targets for the calcium-channel modulators used in the treatment of neurological disorders. J Cardiovasc Pharmacol. 1991;18(Supplement 8)S1-S5.
77. Akaike N, Kostyuk PG, Osipchuk YV. Dihydropyridine-sensitive low threshold calcium channels in isolated rat hypothalamic neurones. J Physiol (Lond). 1989;412:181–191.
78. Phelps CD, Corbett JJ. Migraine and low-tension glaucoma: a case-control study. Invest Ophthalmol Vis Sci. 1985;26:1105–1108.
79. Schmidt R, Oestreich W. Flunarizine in migraine prophylaxis: the clinical experience. J Cardiovasc Pharmacol. 1991;18(Supplement 8):S21-S26.
80. Alps BJ, Calder C, Hass WK, Wilson AD. Comparative protective effects of nicardipine, flunarizine, lidoflazine and nimodipine against ischaemic injury in the hippocampus of the Mongolia gerbil. Br J Pharmacol. 1988;93:877–883.
81. De Ryck M, Van Reempts J, Borgers M, Wauquier A, Janssen PAJ. Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. Stroke. 1989;20:1383–1390.
82. Watanabe Y, Shibuya T. Possible mechanism of sustained neuronal death induced by excessive glutamate and endogenous glutamate release: its protection by flunarizine and presence of glia cells in cultured cerebellar granule cells. Clin Neuropharmacol. 1992;15(pt A):132A–133A.
83. Mermoud A, Faggioni R, Van Melle GD. Double-blind study in the treatment of normal tension glaucoma with naftidrofuryl. Ophthalmologica. 1990;201:145–151.
84. Mermoud A, Faggioni R. Le traitement du glaucome à pression normale avec un antagoniste des recepteurs S2 de la Sérotonine, le naftidrofuryl (Praxilen). Klin Monatsbl Augenheilkd. 1991;198:332–334.
85. Beati D, Mermoud A, Faggioni R. Effet du Naftidrofuryl (Praxilen) dans le glaucome primaire à angle ouvert (GPAO): étude prospective en double insu. Klin Monatsbl Augenheilkd. 1992;200:407–408.
86. Bredt DS, Snyder SH. Nitric oxide: a novel neuronal messenger. Neuron. 1992;8:3–11.
87. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature. 1990;347:768–770.
88. O'Dell TJ, Hawkins RD, Kandel ER, Arancio O. Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. Proc Natl Acad Sci U S A. 1991;88:11285–11289.
89. Dawson TM, Dawson VL, Snyder SH. A novel neuronal messenger molecule in brain: the free radical, nitric oxide. Ann Neurol. 1992;32:297–311.
90. Mayer B, Klatt P, Bohme E, Schmidt K. Regulation of neuronal nitric oxide and cyclic GMP formation by Ca2+. J Neurochem. 1992;59:2024–2029.
91. Garthwaite J, Garthwaite G, Palmer RM, Moncada S. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol. 1989;172:413–416.
92. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol. 1992;149:2736–2741.
93. Wallis RA, Panizzon K, Wasterlain CG. Inhibition of nitric oxide synthase protects against hypoxic neuronal injury. Neuroreport. 1992;3:645–648.
94. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59:1609–1623.
95. Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH. Carbon monoxide: a putative neural messenger. Science. 1993;259:381–384.
96. Knowles RG, Palacios M, Palmer RM, Moncada S. Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A. 1989;86:5159–5162.
97. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109–142.
98. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci U S A. 1991;88:6368–6371.
99. Nowicki JP, Duval D, Poignet H, Scatton B. Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse. Eur J Pharmacol. 1991;204:339–340.
100. Dawson TM, Bredt DS, Fotuhi M, Hwang PM, Snyder SH. Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. Proc Natl Acad Sci U S A. 1991;88:7797–7801.
101. Geyer O, Podos SM, Mittag TW. Nitric oxide synthase: distribution and biochemical properties of the enzyme in the bovine eye. Invest Ophthalmol Vis Sci U S A. 1993;34(Supplement):826.
102. Bredt DS, Glatt CE, Hwang PM, Fotuhi M, Dawson TM, Snyder SH. Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron. 1991;7:615–624.
103. Hope BT, Michael GJ, Knigge KM, Vincent SR. Neuronal NADPH diaphorase is a nitric oxide synthase. Proc Natl Acad Sci U S A. 1991;88:2811–2814.
104. Koh JY, Peters S, Choi DW. Neurons containing NADPH-diaphorase are selectively resistant to quinolinate toxicity. Science. 1986;234:73–76.
105. Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, Richardson EP Jr. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J Neuropathol Exp Neurol. 1987;46:12–27.
106. Uemura Y, Kowall NW, Beal MF. Selective sparing of NADPH-diaphorase-somatostatinneuropeptide Y neurons in ischemic gerbil striatum. Ann Neurol. 1990;27:620–625.
107. Beal MF, Swartz KJ, Finn SF, Mazurek MF, Kowall NW. Neurochemical characterization of excitotoxin lesions in the cerebral cortex. J Neurosci. 1991;11:147–158.
108. Unger JW, Lange W. NADPH-diaphorasepositive cell populations in the human amygdala and temporal cortex: neuroanatomy, peptidergic characteristics and aspects of aging and Alzheimer's disease. Acta Neuropathol. 1992;83:636–646.
109. Sagar SM. NADPH-diaphorase reactive neurons of the rabbit retina: differential sensitivity to excitotoxins and unusual morphologic features. J Comp Neurol. 1990;300:309–319.
110. Kontos HA. Oxygen radicals in CNS damage. Chem Biol Interact. 1989;72:229–255.
111. Granger DN, Hollwarth ME, Parks DA. Ischemiareperfusion injury: role of oxygen-derived free radicals. Acta Physiol Scand. 1986;548(Supplement): 47–63.
112. Juarez CP, Tso MOM, van Heuven WAJ, Hayreh MS, Hayreh SS. Experimental retinal vascular occlusion, II: a clinicopathologic correlative study of simultaneous occlusion of central retinal vein and artery. Int Ophthalmol. 1986;9:77–87.
113. Faberowski N, Stefannsson E, Davidson RC. Local hypothermia protects the retina from ischemia. Invest Ophthalmol Vis Sci. 1989;30:2309–2313.
114. Hearse DJ. Reperfusion-induced injury: a possible role for oxidant stress and its manipulation. Cardiovasc Drugs Ther. 1991;5:225–236.
115. Chan PH, Yurko M, Fishman RA. Phospholipid degradation and cellular edema induced by free radicals in brain cortical slices. J Neurochem. 1982;38:525–531.
116. Braughler JM, Hall ED. Central nervous system trauma and stroke, I: biochemical considerations for oxygen radical formation and lipid peroxidation. Free Radic Biol Med. 1989;6:289–301.
117. Hall ED, Braughler JM. Central nervous system trauma and stroke, II: physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic Biol Med. 1989;6:303–313.
118. Jesberger JA, Richardson JS. Oxygen free radicals and brain dysfunction. Int J Neurosci. 1991;57:1–17.
119. Chan PH, Yurko M, Fishman RA. Phospholipid degradation and cellular edema induced by free radicals in brain cortical slices. J Neurochem. 1982;38:525–531.
120. Wei EP, Kontos HA. Oxygen radicals in cerebral ischemia. Physiologist. 1987;30:122.
121. Kirsch JR, Phelan AM, Lange DG, Traystman RJ. Free radicals detected in brain during reperfusion from global ischemia. Federation Proc. 1987;46:799.
122. Kurihara M. Role of monoamines in experimental spinal cord injury in rats: relationship between Na+-K+-ATPase and lipid peroxidation. J Neurosurg. 1985;62:743–749.
123. Saunders RD, Dugan LL, Demediuk P, Means ED, Horrocks LA, Anderson DK. Effects of methylprednisolone and the combination of α-tocopherol and selenium on arachidonic acid metabolism and lipid peroxidation in traumatized spinal cord tissue. J Neurochem. 1987;49:24–31.
124. Davis RJ, Bulkley GB, Traystman RJ. Role of oxygen-free radicals in focal brain ischemia. Federation Proc. 1987;46:799.
125. Cerchiari EL, Hoel TM, Safar P, Sclabassi RJ. Protective effects of combined superoxide dismutase and deferoxamine on recovery of cerebral blood flow and function after cardiac arrest in dogs. Stroke. 1987;18:869–878.
126. Hara H, Kogure K. Prevention of hippocampus neuronal damage in ischemic gerbils by a novel lipid peroxidation inhibitor (quinazoline derivative). J Pharmacol Exp Ther. 1990;255:906–913.
127. Szabo ME, Droy-Lefaix MT, Doly M, Carre C, Braquet P. Ischemia and reperfusion-induced histologic changes in the rat retina: demonstration of a free radical-mediated mechanism. Invest Ophthalmol Vis Sci. 1991;32:1471–1478.
128. Szabo ME, Droy-Lefaix MT, Dolly M, Braquet P. Ischaemia- and reperfusion-induced Na+, K+, Ca2+ and Mg2+ shifts in rat retina: effects of two free radical scavengers, SOD and EGB 761. Exp Eye Res. 1992;55:39–45.
129. Szabo ME, Droy-Lefaix MT, Doly M, Braquet P. Modification of ischemia/reperfusion-induced ion shifts (Na+, K+, Ca2+ and Mg2+) by free radical scavengers in the rat retina. Ophthalmic Res. 1993;25:1–9.
130. Droy-Lefaix MT, Bonhomme B, Doly M. Protective effect of Ginkgo biloba extract (EGB 761) on free radical-induced changes in the electroretinogram of isolated rat retina. Drugs Exp Clin Res. 1991;17:571–574.
131. Nayak MS, Kita M, Marmor MF. Protection of rabbit retina from ischemic injury by superoxide dismutase and catalase. Invest Ophthalmol Vis Sci. 1993;34:2018–2022.
132. Veriac S, Tissie G, Bonne C. Oxygen free radicals adversely affect the regulation of vascular tone by nitric oxide in the rabbit retina under high intraocular pressure. Exp Eye Res. 1993;56:85–88.
133. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986;320:454–456.
134. Sun AY, Cheng Y, Bu Q, Oldfield F. The biochemical mechanisms of the excitotoxicity of kainic acid: free radical formation. Mol Chem Neuropathol. 1992;17:51–63.
135. Aizenman E, Hartnett KA, Reynolds IJ. Oxygen free radicals regulate NMDA receptor function via a redox modulatory site. Neuron. 1990;5:841–846.
136. Pellegrini-Giampietro DE, Cherici G, Alesiani M, Carla V, Moroni F. Exicitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage. J Neurosci. 1990;10:1035–1041.
137. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62.
138. McNamara JO, Fridovich I. Did radicals strike Lou Gehrig? Nature. 1993;362:20–21.
139. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992;326:1464–1468.
140. Choi DW. Amyotrophic lateral sclerosis and glutamate: too much of a good thing? N Engl J Med. 1992;326:1493–1495.
141. Kinoshita A, Yamada K, Kohmura E, Hayakawa T. Human recombinant superoxide dismutase protects primary cultured neurons against hypoxic injury. Pathobiology. 1991;59:340–344.
142. Ohtsuki T, Matsumoto M, Kuwabara K, et al. Influence of oxidative stress on induced tolerance to ischemia in gerbil hippocampal neurons. Brain Res. 1992;599:246–252.
143. Villegas-Pérez MP, Vidal-Sanz M, Bray GM, Aguayo AJ. Influences of peripheral nerve grafts on the survival and regrowth of axotomized retinal ganglion cells in adult rats. J Neurosci. 1988;8:265–280.
144. Aguayo AJ, Rasminsky M, Bray GM, et al. Degenerative and regenerative responses of injured neurons in the central nervous system of adult mammals. Philos Trans R Soc Lond Biol. 1991;331:337–343.
145. Bray GM, Villegas-Pérez MP, Vidal-Sanz M, Carter DA. Aguayo AJ. Neuronal and nonneuronal influences on retinal ganglion cell survival, axonal regrowth, and connectivity after axotomy. Ann N Y Acad Sci. 1991;633:214–228.
146. Kierstead SA, Rasminsky M, Fukuda Y, Carter DA, Aguayo AJ, Vidal-Sanz M. Electrophysiologic responses in hamster superior colliculus evoked by regenerating retinal axons. Science. 1989;246:255–258.
147. Barker P, Acheson A, Pareek S, Miller FD, Murphy RA. Detection of brain-derived neurotrophic factor (BDNF)-like biological activity and mRNA in sciatic nerve fibroblasts and Schwann cells. Soc Neurosci Abstr. 1990;16:1136.
148. Johnson JE, Barde Y-A, Schwab M, Thoenen H. Brain-derived neurotrophic factor supports the survival of cultured rat retinal ganglion cells. J Neurosci. 1986;6:3031–3038.
149. Thanos S, Bähr M, Barde Y-A, Vanselow J. Survival and axonal elongation of adult rat retinal ganglion cells. Eur J Neurosci. 1989;1:19–26.
150. Ebendal T. Function and evolution in the NGF family and its receptors. J Neurosci Res. 1992;32:461–470.
151. Kromer LF. Nerve growth factor treatment after brain injury prevents neuronal death. Science. 1987;235:214–216.
152. Carmignoto G, Maffei L, Candeo P, Canella R, Comelli C. Effect of NGF on the survival of rat retinal ganglion cells following optic nerve section. J Neurosci. 1989;9:1263–1272.
153. Messersmith DJ, Fabrazzo M, Mocchetti I, Kromer LF. Effects of sciatic nerve transplants after fimbria-fornix lesion: examination of the role of nerve growth factor. Brain Res. 1991;557:293–297.
154. Wilensky JT, Asrani SG, Baca L, Hoick D, Viana M. Waking IOP spikes. Invest Ophthalmol Vis Sci. 1993;34(Supplement):1383.
155. Graham SL, Drance SM, Wijsman K, Mikelberg FS, Douglas GR. Nocturnal hypotension in glaucoma patients. Invest Ophthalmol Vis Sci. 1993;34(Supplement):1286.
156. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. The role of nocturnal hypotension in ocular and optic nerve ischemic disorders. Invest Ophthalmol Vis Sci. 1993;34(Supplement):994.